Philippe CONNES
|
Philippe Connes obtained a PhD in Montpellier in 2003 in the field of exercise physiology and hematology. After a one-year contract in Lyon where he served as a temporary Lecturer, he was recruited in 2004 as a Senior Lecturer in Exercise Physiology at the Laboratory ACTES - Department of Physiology (University of the French West Indies, Pointe-à-Pitre, Guadeloupe). He lead the team “Sickle Cell Trait and Exercise”. In 2008, he obtained a 5 yrs Inserm National Research Contract to work as a researcher in the UMR Inserm 1134 “Integrative Biology of Red Blood Cell” at the Academic Hospital of Pointe-à-Pitre (Guadeloupe). He worked on the pathophysiological mechanisms of sickle cell disease, and more particularly on the role of blood rheology, vascular function, autonomic nervous system activity and inflammation. He got its accreditation to supervise research (HDR) from the University of the French West Indies (Guadeloupe) in 2009. In 2013, he successfully applied to the French University Institute (IUF) as a junior member (5 yrs contract). In 2014, he was promoted on a Full Professor position at the University of Lyon (France). Since that time, he leads the "Vascular Biology and Red Blood Cell" team in the LIBM laboratory (EA7424). He mainly works on the cellular/biological/physiological mechanisms involved in sickle cell disease complications and in other hematological disorders (hereditary spherocytosis, chronic mountain sickness…). He also investigates the acute and chronic effects of exercise on hematological adaptations and red blood cell physiology in healthy individuals and patients with chronic hematological disorders. Philippe obtained several local (Programme Hospitalier de Recherche Clinique locaux/Inter-régionaux, Contrat Plan-Etat Recherche, Bonus Qualité Recherche, Idex Lyon,…), national (French Research National agency, French Blood Center,....), international (Eurostars H2020 program, German Research National Agency (DFG), International Training Network Marie-Curie, FAPESP,…) and private (Erytech Pharma, Hartis Pharma,…) grants/fundings. |
Philippe Connes (philippe.connes @ univ.lyon1.fr)
Institution Université Claude Bernard (Lyon 1) Responsability Team Leader Team: [VBRBC] Position Professor
Publications
|
|
He is internationally recognized in the field of blood rheology, microcirculation and sickle cell disease (ranked 1st and 10th in the field of sickle cell trait and sickle cell disease, respectively, on Expertscape website). He serves as Academic/Assistant Editor for several scientific journals: Clinical Hemorheology and Microcirculation, Frontiers in Physiology (section Red Blood Cell) and Plos One. Philippe Connes is also the Scientific Research referent of the Constitutive Reference Center on Red Blood Cell disorders in Lyon. October 2020, Philippe published 215 international scientific articles, several book chapters, coordinated an international handbook in Exercise Physiology and supervised 20 PhD/post-doc. He is currently an Executive Board member in the European Society of Clinical Hemorheology and Microcirculation (ESCHM), the French club of Red Blood Cell and Iron (Club du Globule Rouge et du Fer) and the International Society for Clinical Hemorheology (ISCH). Philippe is also the vice-dean of the Doctorate School EDISS 205 (Université Claude Bernard Lyon 1) since September 2019. | |
1. The frequency of vaso-occulusive crises in sickle cell anaemia patiens is influenced by sympathovagal imbalance and blood viscosity. 2. Acetazolamide treatment reduces blood viscosity, right ventricular hypertrophy and pulmonary and total vascular resistance in the rat having undergone a chronic hypoxia. 3. Six weeks of adapted re-training in children affected by sickle cless anaemia improves breathing efficiency, reduces hemolysis and nitrosative stress, and increases the amount of nitrite circulation. 4. In Gaucher’s disease, we can observe an increase in blood viscosity, red blood cell to endothelium bonding, the stiffness and clustering of erythrocites. 5. The sickle cell trait increases the risk of vascular dysfunction and complications in patients with type II diabetes. | |
